Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEHistaminephosphateCat.No.:HY-A0129CASNo.:51-74-1Synonyms:Histaminediphosphate分?式:C?H??N?O?P?分?量:307.14作?靶點(diǎn):HistamineReceptor;EndogenousMetabolite作?通路:GPCR/GProtein;Immunology/Inflammation;NeuronalSignaling;MetabolicEnzyme/Protease儲(chǔ)存?式:4°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性數(shù)據(jù)體外實(shí)驗(yàn)H2O:100mg/mL(325.58mM;Needultrasonic)DMSO:1.43mg/mL(4.66mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM3.2558mL16.2792mL32.5584mL5mM0.6512mL3.2558mL6.5117mL10mM0.3256mL1.6279mL3.2558mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C儲(chǔ)存時(shí)，請?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請依序添加每種溶劑：PBSSolubility:50mg/mL(162.79mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性Histamine(phosphate)?個(gè)強(qiáng)的histamine受體的激活劑和?管擴(kuò)張神經(jīng)劑，能夠激活?氧化氮合成酶。戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?CancerCell.2022Sep1;S1535-6108(22)00378-6.?BrJPharmacol.2021Jan27.?Mbio.2022Aug24;e0200422.?FrontPharmacol.2019Nov15;10:1380.?JCellCommunSignal.2022Oct25.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].RietveldSetal.Theinfluenceofrespiratorysoundsonbreathlessnessinchildrenwithasthma:asymptom-perceptionapproach.[2].RietveldSetal.Theinfluenceofrespiratorysoundsonbreathlessnessinchildrenwithasthma:asymptom-perceptionapproach.HealthPsychol.1997Nov;16(6):547-53.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-